Research progress in tuberculosis DNA vaccine and its action mechanism
LI Jun-li, ZHAO Ai-hua
Division of Tuberculosis Vaccine and Allergen, Institute of Biological Product Control, National Institutes for Food and Drug Control, Beijing 102629, China
Abstract:In order to achieve the grand goal of eliminating tuberculosis (TB) globally by 2050, it is urgently needed to develop novel TB vaccines and vaccination strategies. Although Bacille Calmette-Guérin (BCG) has been succeeded in protecting children from miliary tuberculosis and tuberculous meningitis, its protective effect on adult pulmonary tuberculosis (PTB) is still weak (0-80%). To date, a dozens of novel TB vaccines, including first-generation and second-generation vaccines, are in different stages of preclinical or clinical research. As the third-generation vaccine, nucleic acid vaccines have gradually entered people's field of vision with the development of medical technology. This review mainly summarizes the immunological mechanism of TB DNA vaccine, the current status of TB DNA vaccine research, the strategy of TB DNA vaccine immunity enhancement, and the problems and application prospects of TB DNA vaccine. We hope to provide new ideas and perspectives for the development of safer and more efficient novel TB DNA vaccines.
李军丽, 赵爱华. 结核病DNA疫苗及其作用机制研究进展[J]. 中国人兽共患病学报, 2022, 38(3): 226-235.
LI Jun-li, ZHAO Ai-hua. Research progress in tuberculosis DNA vaccine and its action mechanism. Chinese Journal of Zoonoses, 2022, 38(3): 226-235.
[1] Blevins SM, Bronze MS.Robert Koch and the ‘golden age’ of bacteriology[J]. Int J Infect Dis, 2010,14(9):e744-751. DOI:10.1016/j.ijid.2009.12.003 [2] Moon MS.Tuberculosis of spine: current views in diagnosis and management[J]. Asian Spine J, 2014 ,8(1):97-111. DOI:10.4184/asj.2014.8.1.97 [3] Mustafa AS.Mycobacterial gene cloning and expression, comparative genomics, bioinformatics and proteomics in relation to the development of new vaccines and diagnostic reagents[J]. Med Princ Pract, 2005,14(Suppl 1):27-34. DOI:10.1159/000086182 [4] Hershkovitz I, Donoghue HD, Minnikin DE, et al.Tuberculosis origin: the neolithic scenario[J]. Tuberculosis (Edinb), 2015,95(Suppl 1):S122-6. DOI:10.1016/j.tube.2015.02.021 [5] World Health Organization.Global tuberculosis report 2021[R]. Geneva: WHO, 2021. [6] Calmette A.Preventive vaccination against tuberculosis with BCG[J]. Proc R Soc Med, 1931,24(11):1481-1490. [7] Trunz BB, Fine P, Dye C.Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness[J]. Lancet, 2006,367(9517):1173-1180. DOI:10.1016/S0140-6736(06)68507-3 [8] Andersen P, Kaufmann SH.Novel vaccination strategies against tuberculosis[J]. Cold Spring Harb Perspect Med, 2014,4(6):a018523. DOI:10.1101/cshperspect.a018523 [9] Andersen P, Doherty TM.The success and failure of BCG - implications for a novel tuberculosis vaccine[J]. Nat Rev Microbiol, 2005,3(8):656-662. DOI:10.1038/nrmicro1211 [10] Abubakar I, Pimpin L, Ariti C, et al. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis [J]. Health Technol Assess, 2013,17(37):1-372, v-vi. DOI:10.3310/hta17370 [11] Li J, Zhao A, Tang J, et al.Tuberculosis vaccine development: from classic to clinical candidates[J]. Eur J Clin Microbiol Infect Dis, 2020,39(8):1405-1425. DOI:10.1007/s10096-020-03843-6 [12] Wolff JA, Malone RW, Williams P, et al.Direct gene transfer into mouse muscle in vivo[J]. Science, 1990,247(4949 Pt 1):1465-1468. DOI:10.1126/science.1690918 [13] Kutzler MA, Weiner DB.DNA vaccines: ready for prime time[J]. Nat Rev Genet, 2008,9(10):776-788. DOI:10.1038/nrg2432 [14] Ingolotti M, Kawalekar O, Shedlock DJ, et al.DNA vaccines for targeting bacterial infections[J]. Expert Rev Vaccines, 2010,9(7):747-763. DOI:10.1586/erv.10.57 [15] Jahanafrooz Z, Baradaran B, Mosafer J, et al.Comparison of DNA and mRNA vaccines against cancer[J]. Drug Discov Today, 2020,25(3):552-560. DOI:10.1016/j.drudis.2019.12.003 [16] Mohan T, Verma P, Rao DN.Novel adjuvants & delivery vehicles for vaccines development: a road ahead[J]. Indian J Med Res, 2013,138(5):779-795. [17] Renshaw PS, Panagiotidou P, Whelan A, et al.Conclusive evidence that the major T-cell antigens of the Mycobacterium tuberculosis complex ESAT-6 and CFP-10 form a tight, 1∶1 complex and characterization of the structural properties of ESAT-6, CFP-10, and the ESAT-6*CFP-10 complex[J]. J Biol Chem, 2002,277(24):21598-21603. DOI:10.1074/jbc.M201625200 [18] 施瑞洁,韩梦箐,马娟,等. 结核T细胞酶联免疫斑点试验在诊断结核病中的临床应用价值[J]. 陕西医学杂志, 2018, 47(6): 800-804. [19] 石洁, 朱岩昆,马晓光,等. 结核分枝杆菌早期分泌靶抗原和抗原85B融合蛋白的原核表达及其在血清学检测中的初步应用[J].中国病原生物学志, 2015, 10(5): 389-392. DOI:10.13350/j.cjpb.150502 [20] Vordermeier HM, Whelan A, Cockle PJ, et al.Use of synthetic peptides derived from the antigens ESAT-6 and CFP-10 for differential diagnosis of bovine tuberculosis in cattle[J]. Clin Diagn Lab Immunol, 2001,8(3):571-578. DOI:10.1128/CDLI.8.3.571-578.2001 [21] Kamath AT, Feng CG, Macdonald M, et al.Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis[J]. Infect Immun, 1999,67(4):1702-1707. DOI:10.1128/IAI.67.4.1702-1707.1999 [22] 王雪梅,王英,薛玉芹,等. 结核病DNA疫苗pVAX1/ESAT-6的构建、鉴定及免疫效应评价[J].南方医科大学学报,2013,33(7):945-950. [23] Maue AC, Waters WR, Palmer MV, et al.An ESAT-6:CFP10 DNA vaccine administered in conjunction with Mycobacterium bovis BCG confers protection to cattle challenged with virulent M. bovis[J]. Vaccine, 2007,25(24):4735-4746. DOI:10.1016/j.vaccine.2007.03.052 [24] Cervantes-Villagrana AR, Hernández-Pando R, Biragyn A, et al.Prime-boost BCG vaccination with DNA vaccines based in β-defensin-2 and mycobacterial antigens ESAT6 or Ag85B improve protection in a tuberculosis experimental model[J]. Vaccine, 2013,31(4):676-684. DOI:10.1016/j.vaccine.2012.11.042 [25] Wang QM, Kang L, Wang XH.Improved cellular immune response elicited by a ubiquitin-fused ESAT-6 DNA vaccine against Mycobacterium tuberculosis[J]. Microbiol Immunol, 2009,53(7):384-390. DOI:10.1111/j.1348-0421.2009.00138.x [26] Xu J, Xu W, Chen X, et al.Recombinant DNA vaccine of the early secreted antigen ESAT-6 by Mycobacterium tuberculosis and Flt3 ligand enhanced the cell-mediated immunity in mice[J]. Vaccine, 2008,26(35):4519-4525. DOI:10.1016/j.vaccine.2008.06.044 [27] Jiang Q, Zhang J, Chen X, et al.A novel recombinant DNA vaccine encoding Mycobacterium tuberculosis ESAT-6 and FL protects against Mycobacterium tuberculosis challenge in mice[J]. J Biomed Res, 2013,27(5):406-420. DOI:10.7555/JBR.27.20120114 [28] Lowrie DB, Tascon RE, Bonato VL, et al.Therapy of tuberculosis in mice by DNA vaccination[J]. Nature, 1999,400(6741):269-271. [29] Yuan W, Dong N, Zhang L, et al.Immunogenicity and protective efficacy of a tuberculosis DNA vaccine expressing a fusion protein of Ag85B-Esat6-HspX in mice[J]. Vaccine, 2012,30(14):2490-2497. DOI:10.1016/j.vaccine.2011.06.029 [30] Liang Y, Wu X, Zhang J, et al.The treatment of mice infected with multi-drug-resistant Mycobacterium tuberculosis using DNA vaccines or in combination with rifampin[J]. Vaccine, 2008,26(35):4536-4450. DOI:10.1016/j.vaccine.2008 [31] Liang Y, Bai X, Zhang J, et al.Ag85A/ESAT-6 chimeric DNA vaccine induces an adverse response in tuberculosis-infected mice[J]. Mol Med Rep, 2016,14(2):1146-1152. DOI:10.3892/mmr.2016.5364 [32] Dey B, Jain R, Khera A, et al.Boosting with a DNA vaccine expressing ESAT-6 (DNAE6) obliterates the protection imparted by recombinant BCG (rBCGE6) against aerosol Mycobacterium tuberculosis infection in guinea pigs[J]. Vaccine, 2009,28(1):63-70. DOI:10.1016/j.vaccine.2009.09.121 [33] Abou-Zeid C, Ratliff TL, Wiker HG, et al.Characterization of fibronectin-binding antigens released by Mycobacterium tuberculosis and Mycobacterium bovis BCG[J]. Infect Immun, 1988,56(12):3046-3051. DOI:10.1128/iai.56.12.3046-3051.1988 [34] Belisle JT, Vissa VD, Sievert T, et al.Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis[J]. Science, 1997,276(5317):1420-1422. DOI:10.1126/science.276.5317.1420 [35] Kuo CJ, Ptak CP, Hsieh CL, et al.Elastin, a novel extracellular matrix protein adhering to mycobacterial antigen 85 complex[J]. J Biol Chem, 2013,288(6):3886-3896. DOI:10.1074/jbc.M112.415679 [36] Dorhoi A, Reece ST, Kaufmann SH.For better or for worse: the immune response against Mycobacterium tuberculosis balances pathology and protection[J]. Immunol Rev, 2011,240(1):235-251. DOI:10.1111/j.1600-065X.2010.00994.x [37] Al-Attiyah R, Mustafa AS, Abal AT, et al.In vitro cellular immune responses to complex and newly defined recombinant antigens of Mycobacterium tuberculosis[J]. Clin Exp Immunol, 2004,138(1):139-144. DOI:10.1111/j.1365-2249.2004.02609.x [38] Macedo GC, Bozzi A, Weinreich HR, et al.Human T cell and antibody-mediated responses to the Mycobacterium tuberculosis recombinant 85A, 85B, and ESAT-6 antigens[J]. Clin Dev Immunol, 2011,2011:351573. DOI:10.1155/2011/351573 [39] Karbalaei Zadeh Babaki M, Soleimanpour S, Rezaee SA. Antigen 85 complex as a powerful Mycobacterium tuberculosis immunogene: biology, immune-pathogenicity, applications in diagnosis, and vaccine design[J]. Microb Pathog, 2017,112:20-29. DOI:10.1016/j.micpath.2017.08.040 [40] Li F, Kang H, Li J, et al.Subunit vaccines consisting of antigens from dormant and replicating bacteria show promising therapeutic effect against Mycobacterium bovis BCG latent infection[J]. Scand J Immunol, 2017,85(6):425-432. DOI:10.1111/sji.12556 [41] Huygen K, Content J, Denis O, et al.Immunogenicity and protective efficacy of a tuberculosis DNA vaccine[J]. Nat Med, 1996,2(8):893-898. DOI:10.1038/nm0896-893 [42] D’Souza S, Rosseels V, Romano M, et al. Mapping of murine Th1 helper T-Cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis[J]. Infect Immun, 2003,71(1):483-493. DOI:10.1128/IAI.71.1.483-493.2003 [43] Tanghe A, D’Souza S, Rosseels V, et al. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting[J]. Infect Immun, 2001,69(5):3041-3047. DOI:10.1128/IAI.69.5.3041-3047.2001 [44] Xu Y, Yang E, Wang J, et al.Prime-boost bacillus Calmette-Guérin vaccination with lentivirus-vectored and DNA-based vaccines expressing antigens Ag85B and Rv3425 improves protective efficacy against Mycobacterium tuberculosis in mice[J]. Immunology, 2014,143(2):277-286. DOI:10.1111/imm.12308 [45] Komine-Aizawa S, Jiang J, Mizuno S, et al.MHC-restricted Ag85B-specific CD8+T cells are enhanced by recombinant BCG prime and DNA boost immunization in mice[J]. Eur J Immunol, 2019,49(9):1399-1414. DOI:10.1002/eji.201847988 [46] Zhang X, Divangahi M, Ngai P, et al.Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: Enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene[J]. Vaccine, 2007,25(7):1342-1352. DOI:10.1016/j.vaccine.2006.09.089 [47] Sun L, Yuan Q, Xu T, et al.Novel adjuvant for immunization against tuberculosis: DNA vaccine expressing Mycobacterium tuberculosis antigen 85A and interleukin-15 fusion product elicits strong immune responses in mice[J]. Biotechnol Lett, 2017,39(8):1159-1166. DOI:10.1007/s10529-017-2342-1 [48] Mir FA, Kaufmann SH, Eddine AN.A multicistronic DNA vaccine induces significant protection against tuberculosis in mice and offers flexibility in the expressed antigen repertoire[J]. Clin Vaccine Immunol, 2009,16(10):1467-1475. DOI:10.1128/CVI.00237-09 [49] Yao W, Liu S, Qu X, et al.Enhanced immune response and protection efficacy of a DNA vaccine constructed by linkage of the Mycobacterium tuberculosis Ag85B-encoding gene with the BVP22-encoding gene[J]. J Med Microbiol, 2009,58(Pt 4):462-468. DOI:10.1099/jmm.0.004267-0 [50] Mustafa AS.Development of new vaccines and diagnostic reagents against tuberculosis[J]. Mol Immunol, 2002, 39(1/2), 113-119. DOI:10.1016/s0161-5890(02)00048-2 [51] Sefidi-Heris Y, Jahangiri A, Mokhtarzadeh A, et al. Recent progress in the design of DNA vaccines against tuberculosis [J]. Drug Discov Today, 2020,11:S1359-6446(20)30345-30347. DOI:10.1016/j.drudis.2020.09.005 [52] Tascon RE, Colston MJ, Ragno S, et al.Vaccination against tuberculosis by DNA injection[J]. Nat Med, 1996,2(8):888-892. DOI:10.1038/nm0896-888 [53] Dai W, Huang H, Yuan Y, et al.Comparative study on the immunogenicity between Hsp70 DNA vaccine and Hsp65 DNA vaccine in human Mycobacterium tuberculosis[J]. J Tongji Med Univ, 2001,21(3):181-183. DOI:10.1007/BF02886423 [54] Ferraz JC, Stavropoulos E, Yang M, et al.A heterologous DNA priming-Mycobacterium bovis BCG boosting immunization strategy using mycobacterial Hsp70, Hsp65, and Apa antigens improves protection against tuberculosis in mice[J]. Infect Immun, 2004,72(12):6945-6950. DOI:10.1128/IAI.72.12.6945-6950.2004 [55] Gonçalves ED, Bonato VL, da Fonseca DM, et al. Improve protective efficacy of a TB DNA-HSP65 vaccine by BCG priming[J]. Genet Vaccines Ther, 2007,5:7. DOI:10.1186/1479-0556-5-7 [56] Pelizon AC, Martins DR, Zorzella-Pezavento SF, et al.Neonatal BCG immunization followed by DNAhsp65 boosters: highly immunogenic but not protective against tuberculosis a-paradoxical effect of the vector[J]. Scand J Immunol, 2010,71(2):63-69. DOI:10.1111/j.1365-3083.2009.02352.x [57] Kaneda Y, Yamamoto S, Nakajima T.Development of HVJ envelope vector and its application to gene therapy[J]. Adv Genet, 2005,53:307-332. [58] Kita Y, Tanaka T, Yoshida S, et al.Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model[J]. Vaccine, 2005, 23:2132-2135. DOI:10.1016/j.vaccine.2005.01.057 [59] Yoshida S, Tanaka T, Kita Y, et al.DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation[J]. Vaccine, 2006,24:1191-1204. DOI:10.1016/j.vaccine.2005.08.103 [60] Okada M, Kita Y, Nakajima T, et al.Evaluation of a novel vaccine (HVJ-liposome/HSP65 DNA+IL-12 DNA) against tuberculosis using the cynomologus monkey model of TB[J]. Vaccine, 2007,25:2990-2993. DOI:10.1016/j.vaccine.2007.01.014 [61] Changhong S, Hai Z, Limei W, et al.Therapeutic efficacy of a tuberculosis DNA vaccine encoding heat shock protein 65 of Mycobacterium tuberculosis and the human interleukin 2 fusion gene[J]. Tuberculosis (Edinb), 2009,89(1):54-61. DOI:10.1016/j.tube.2008.09.005 [62] 胡方靖,武军驻. pIHsp65GM的构建及其对结核杆菌感染小鼠的保护[J]. 免疫学杂志,2011,27(8):666-671. DOI:10.13431/j.cnki.immunol.j.20110158 [63] Wang Q.Ub combination enhanced cellular immune response elicited by HSP65 DNA vaccine against Mycobacterium tuberculosis[J]. World J Vaccines, 2013,3: 89. [64] Lambert PH, Laurent PE.Intradermal vaccine delivery: will new delivery systems transform vaccine administration[J]. Vaccine, 2008,26(26):3197-3208. DOI:10.1016/j.vaccine.2008.03.095 [65] Mellott AJ, Forrest ML, Detamore MS.Physical non-viral gene delivery methods for tissue engineering[J]. Ann Biomed Eng, 2013,41(3):446-468. DOI:10.1007/s10439-012-0678-1 [66] Soltani F, Parhiz H, Mokhtarzadeh A, et al.Synthetic and biological vesicular nano-carriers designed for gene delivery[J]. Curr Pharm Des, 2015,21(42):6214-6235. DOI:10.2174/1381612821666151027153410 [67] Wei W, Qi X, Li J, et al.Smart macroporous salecan/poly(N,N-diethylacrylamide) semi-IPN hydrogel for anti-inflammatory drug delivery[J]. ACS Biomater Sci Eng, 2016, 2(8):1386-1394. DOI:10.1021/acsbiomaterials.6b00318 [68] Vicari AP, Caux C.Chemokines in cancer[J]. Cytokine Growth Factor Rev, 2002,13(2):143-54. DOI:10.1016/s1359-6101(01)00033-8 [69] Lotze MT, Tracey KJ.High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal[J]. Nat Rev Immunol, 2005,5(4):331-342. DOI:10.1038/nri1594 [70] Esche C, Stellato C, Beck LA.Chemokines: key players in innate and adaptive immunity[J]. J Invest Dermatol, 2005,125(4):615-628. DOI:10.1111/j.0022-202X.2005.23841.x [71] Ingolotti M, Kawalekar O, Shedlock DJ, et al.DNA vaccines for targeting bacterial infections[J]. Expert Rev Vaccines, 2010,9(7):747-763. DOI:10.1586/erv.10.57 [72] Tavernier G, Andries O, Demeester J, et al.mRNA as gene therapeutic: how to control protein expression[J]. J Control Release, 2011,150(3):238-247. DOI:10.1016/j.jconrel.2010.10.020 [73] Irvine DJ, Hanson MC, Rakhra K, et al.Synthetic nanoparticles for vaccines and immunotherapy[J]. Chem Rev, 2015,115(19):11109-11146. DOI:10.1021/acs.chemrev.5b00109 [74] Food and Drug Administration. Considerations for plasmid DNA vaccines for infectious disease indications, 2007[EB/OL].(2014-03-26)[2021-07-25]. http://www. fda. gov/cber/guidelines. htm [75] Khalili S, Rahbar MR, Dezfulian MH, et al.In silico analyses of Wilms tumor protein to designing a novel multi-epitope DNA vaccine against cancer[J]. J Theor Biol, 2015, 379:66-78. DOI:10.1016/j.jtbi.2015.04.026 [76] Vani J, Shaila MS, Chandra NR, et al.A combined immuno-informatics and structure-based modeling approach for prediction of T cell epitopes of secretory proteins of Mycobacterium tuberculosis[J]. Microbes Infect, 2006,8(3):738-746. DOI:10.1016/j.micinf.2005.09.012 [77] Wang J, Zhang H, Wang H.Analysis of predicted CD8+ T cell epitopes from proteins encoded by the specific RD regions of Mycobacterium tuberculosis for vaccine development and specific diagnosis[J]. Mol Biol Rep, 2010,37(4):1793-1799. DOI:10.1007/s11033-009-9613-4 [78] Mustafa AS.In silico analysis and experimental validation of Mycobacterium tuberculosis-specific proteins and peptides of Mycobacterium tuberculosis for immunological diagnosis and vaccine development[J]. Med Princ Pract, 2013,22(Suppl 1):43-51. DOI:10.1159/000354206 [79] Khalili S, Rasaee MJ, Bamdad T, et al.A novel molecular design for a hybrid phage-DNA construct against DKK1[J]. Mol Biotechnol, 2018,60(11):833-842. DOI:10.1007/s12033-018-0115-2 [80] Rezaei T, Khalili S, Baradaran B, et al.Recent advances on HIV DNA vaccines development: stepwise improvements to clinical trials[J]. J Control Release, 2019,316:116-137. DOI:10.1016/j.jconrel.2019.10.045